Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBT (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBT for 11 consecutive years, with -$92.2 million as the latest value for Q4 2025.

  • Quarterly EBT rose 26.69% to -$92.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$411.8 million through Dec 2025, up 15.35% year-over-year, with the annual reading at -$411.8 million for FY2025, 15.35% up from the prior year.
  • EBT for Q4 2025 was -$92.2 million at Intellia Therapeutics, up from -$104.8 million in the prior quarter.
  • The five-year high for EBT was -$46.2 million in Q1 2021, with the low at -$143.7 million in Q1 2022.
  • Average EBT over 5 years is -$104.0 million, with a median of -$104.2 million recorded in 2022.
  • The sharpest move saw EBT crashed 211.02% in 2022, then soared 30.43% in 2023.
  • Over 5 years, EBT stood at -$79.9 million in 2021, then crashed by 31.06% to -$104.7 million in 2022, then decreased by 21.67% to -$127.4 million in 2023, then increased by 1.27% to -$125.8 million in 2024, then rose by 26.69% to -$92.2 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$92.2 million, -$104.8 million, and -$102.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.